NCT06238544View on ClinicalTrials.gov

Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 6, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG

HRS-5965 tablets

HRS-5965 tablets until the end of study treatment

DRUG

HRS-5965 Capsules

HRS-5965 capsules.

Trial Locations (2)

100730

RECRUITING

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

300020

RECRUITING

The Blood Disease Hospital of the Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Chengdu Suncadia Medicine Co., Ltd.

INDUSTRY